Mondana H Ghias1, Andrew D Johnston1, Allison J Kutner1, Robert G Micheletti2, H Dean Hosgood3, Steven R Cohen4. 1. Division of Dermatology, Department of Internal Medicine, Albert Einstein College of Medicine, Bronx, New York. 2. Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York. 4. Division of Dermatology, Department of Internal Medicine, Albert Einstein College of Medicine, Bronx, New York. Electronic address: srcohen@montefiore.org.
Abstract
BACKGROUND: The permanent disfigurement associated with hidradenitis suppurativa (HS) necessitates early aggressive disease intervention. Although limited data support the use of infliximab (IFX) in HS, the efficacy of high-dose, high-frequency IFX has yet to be defined. OBJECTIVE: To evaluate the efficacy of IFX 7.5 to 10 mg/kg, with a maintenance frequency every 4 weeks. METHODS: Prospective analysis of 42 patients initiating IFX 7.5 mg/kg every 4 weeks (IFX 7.5) and 16 patients receiving dose escalation to IFX 10 mg/kg every 4 weeks (IFX 10) between March 1, 2018, and February 28, 2019. The primary outcome measure (clinical response) was the proportion of patients with Physician Global Assessment of clear, minimal, or mild (score of 0-2) HS with at least a 2-grade improvement from baseline scores. RESULTS: The proportion of patients achieving a clinical response after initiating IFX 7.5 was 20 of 42 (47.6%) at week 4 and 17 of 24 (70.8%) at week 12. For patients receiving dose escalation to IFX 10 because of incomplete initial response, 6 of 16 (37.5%) achieved clinical response at week 4 and 6 of 12 (50%) at week 12. CONCLUSIONS: Initiation of IFX 7.5 every 4 weeks, with possible dose escalation to IFX 10, if needed, provides optimal mitigation of HS-related disease activity.
BACKGROUND: The permanent disfigurement associated with hidradenitis suppurativa (HS) necessitates early aggressive disease intervention. Although limited data support the use of infliximab (IFX) in HS, the efficacy of high-dose, high-frequency IFX has yet to be defined. OBJECTIVE: To evaluate the efficacy of IFX 7.5 to 10 mg/kg, with a maintenance frequency every 4 weeks. METHODS: Prospective analysis of 42 patients initiating IFX 7.5 mg/kg every 4 weeks (IFX 7.5) and 16 patients receiving dose escalation to IFX 10 mg/kg every 4 weeks (IFX 10) between March 1, 2018, and February 28, 2019. The primary outcome measure (clinical response) was the proportion of patients with Physician Global Assessment of clear, minimal, or mild (score of 0-2) HS with at least a 2-grade improvement from baseline scores. RESULTS: The proportion of patients achieving a clinical response after initiating IFX 7.5 was 20 of 42 (47.6%) at week 4 and 17 of 24 (70.8%) at week 12. For patients receiving dose escalation to IFX 10 because of incomplete initial response, 6 of 16 (37.5%) achieved clinical response at week 4 and 6 of 12 (50%) at week 12. CONCLUSIONS: Initiation of IFX 7.5 every 4 weeks, with possible dose escalation to IFX 10, if needed, provides optimal mitigation of HS-related disease activity.
Authors: Kristina Navrazhina; Sandra Garcet; Juana Gonzalez; David Grand; John W Frew; James G Krueger Journal: J Invest Dermatol Date: 2021-03-22 Impact factor: 7.590
Authors: Ester Del Duca; Paola Morelli; Luigi Bennardo; Cosimo Di Raimondo; Steven Paul Nisticò Journal: Int J Mol Sci Date: 2020-11-10 Impact factor: 5.923
Authors: Kristina Navrazhina; Sandra Garcet; John W Frew; Xiuzhong Zheng; Israel Coats; Emma Guttman-Yassky; James G Krueger Journal: J Am Acad Dermatol Date: 2021-07-30 Impact factor: 11.527
Authors: Pim Aarts; Koen Dudink; Allard R J V Vossen; Kelsey R van Straalen; Christine B Ardon; Errol P Prens; Hessel H van der Zee Journal: Drugs Date: 2021-07-20 Impact factor: 9.546